Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients.
Silvia MedinaSusana Sainz de la MazaNoelia VillarrubiaRoberto Álvarez-LafuenteLucienne Costa-FrossardRafael ArroyoEnric MonrealAmalia Tejeda VelardeEulalia Rodríguez-MartínErnesto RoldánJosé C Álvarez-CermeñoLuisa Maria VillarPublished in: Annals of clinical and translational neurology (2019)
Teriflunomide induces a specific reduction in effector T and B cells that have shown to play a role in MS course and an increase in immunomodulatory cells. Particularly, this drug induces the expression of PD-L1, a molecule involved in tolerance to autoantigens, which can contribute to inhibit the abnormal immune response taking place in MS.
Keyphrases
- mass spectrometry
- multiple sclerosis
- dendritic cells
- immune response
- ms ms
- end stage renal disease
- regulatory t cells
- ejection fraction
- chronic kidney disease
- induced apoptosis
- newly diagnosed
- poor prognosis
- prognostic factors
- cell cycle arrest
- emergency department
- toll like receptor
- oxidative stress
- cell proliferation
- signaling pathway
- patient reported outcomes
- adverse drug